ID: ALA5219344

Max Phase: Preclinical

Molecular Formula: C11H7NO

Molecular Weight: 169.18

Representations

Canonical SMILES:  C#Cc1ccc(-c2cnco2)cc1

Standard InChI:  InChI=1S/C11H7NO/c1-2-9-3-5-10(6-4-9)11-7-12-8-13-11/h1,3-8H

Standard InChI Key:  CYRYZDZQFDRTHD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 169.18

Molecular Weight (Monoisotopic): 169.0528

AlogP: 2.32

#Rotatable Bonds: 1

Polar Surface Area: 26.03

Molecular Species: NEUTRAL

HBA: 2

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 2

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.80

CX LogP: 1.63

CX LogD: 1.63

Aromatic Rings: 2

Heavy Atoms: 13

QED Weighted: 0.61

Np Likeness Score: -1.16

References

1. Narayanan D, Tran KT, Pallesen JS, Solbak SMØ, Qin Y, Mukminova E, Luchini M, Vasilyeva KO, González Chichón D, Goutsiou G, Poulsen C, Haapanen N, Popowicz GM, Sattler M, Olagnier D, Gajhede M, Bach A..  (2022)  Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery.,  65  (21.0): [PMID:36263945] [10.1021/acs.jmedchem.2c00830]

Source

Source(1):

• Scientific Literature